ATE430747T1 - 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren - Google Patents

2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren

Info

Publication number
ATE430747T1
ATE430747T1 AT05853157T AT05853157T ATE430747T1 AT E430747 T1 ATE430747 T1 AT E430747T1 AT 05853157 T AT05853157 T AT 05853157T AT 05853157 T AT05853157 T AT 05853157T AT E430747 T1 ATE430747 T1 AT E430747T1
Authority
AT
Austria
Prior art keywords
pyrimidinyl
pyrazolopyridine
kinase inhibitors
erbb kinase
erbb
Prior art date
Application number
AT05853157T
Other languages
English (en)
Inventor
David Edward Uehling
Kirk Lawrence Stevens
Scott Dickerson
Alex Gregory Waterson
Philip Anthony Harris
Douglas M Sammond
Robert Dale Hubbard
Holly Kathleen Stemerson
Joseph W Wilson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE430747T1 publication Critical patent/ATE430747T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05853157T 2004-12-21 2005-12-06 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren ATE430747T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63792804P 2004-12-21 2004-12-21
US70907905P 2005-08-17 2005-08-17
PCT/US2005/044166 WO2006068826A2 (en) 2004-12-21 2005-12-06 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE430747T1 true ATE430747T1 (de) 2009-05-15

Family

ID=36588699

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05853157T ATE430747T1 (de) 2004-12-21 2005-12-06 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren

Country Status (6)

Country Link
EP (1) EP1828185B1 (de)
JP (1) JP5132319B2 (de)
AT (1) ATE430747T1 (de)
DE (1) DE602005014382D1 (de)
ES (1) ES2325035T3 (de)
WO (1) WO2006068826A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7812022B2 (en) 2004-12-21 2010-10-12 Glaxosmithkline Llc 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
AU2006209216A1 (en) * 2005-01-25 2006-08-03 Galenea Corp Substituted arylamine compounds and their use as 5-HT6 modulators
CN101326182B (zh) * 2005-12-05 2011-09-28 史密丝克莱恩比彻姆公司 2-嘧啶基吡唑并吡啶ErbB激酶抑制剂
US8258129B2 (en) * 2006-07-06 2012-09-04 Boehringer Ingelheim International Gmbh 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
JP5693951B2 (ja) * 2007-04-24 2015-04-01 アストラゼネカ エービー プロテインキナーゼの阻害剤
US8067409B2 (en) 2007-11-27 2011-11-29 Abbott Laboratories Protein kinase inhibitors
HUE030912T2 (en) 2008-02-15 2017-06-28 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
EP2300013B2 (de) 2008-05-21 2024-11-13 Takeda Pharmaceutical Company Limited Phosphor-derivate als kinase-inhibitoren
WO2010070060A1 (en) * 2008-12-19 2010-06-24 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
CN102459264A (zh) * 2009-05-27 2012-05-16 雅培制药有限公司 激酶活性的嘧啶抑制剂
EP2435435B1 (de) * 2009-05-27 2014-01-29 AbbVie Inc. Pyrimidinhemmer der kinaseaktivität
CA2778265A1 (en) * 2009-11-02 2011-05-05 Abbott Laboratories Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition
EP2360158A1 (de) * 2010-02-18 2011-08-24 Almirall, S.A. Pyrazolderivate als JAK-Inhibitoren
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
EP2402336A1 (de) * 2010-06-29 2012-01-04 Basf Se Pyrazolopyridin-Verbindungen
EP2463289A1 (de) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]Pyridazin-Derivate als AS JAK-Hemmer
EP2704572B1 (de) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Verfahren zur hemmung der zellproliferation bei efgr-vermitteltem krebs
MY161925A (en) * 2011-07-27 2017-05-15 Astrazeneca Ab 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
EP2554544A1 (de) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1H-)-on-Derivate als JAK-Inhibitoren
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Egfr発動性がんの細胞増殖阻害用化合物
SI2925757T1 (en) * 2012-11-19 2018-01-31 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN104829613B (zh) * 2015-04-13 2020-06-09 赤峰蒙广生物科技有限公司 二芳基取代的吡唑并环类衍生物、其制备方法及其在医药领域的应用
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
EA202192552A1 (ru) 2019-03-29 2021-12-17 Астразенека Аб Осимертиниб для применения в лечении немелкоклеточного рака легкого
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CN116348458A (zh) 2019-08-14 2023-06-27 因赛特公司 作为cdk2抑制剂的咪唑基嘧啶基胺化合物
CN119930611A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa

Also Published As

Publication number Publication date
ES2325035T3 (es) 2009-08-24
WO2006068826A3 (en) 2006-10-05
EP1828185A2 (de) 2007-09-05
JP5132319B2 (ja) 2013-01-30
DE602005014382D1 (de) 2009-06-18
EP1828185B1 (de) 2009-05-06
WO2006068826A2 (en) 2006-06-29
JP2008524220A (ja) 2008-07-10

Similar Documents

Publication Publication Date Title
DE602005014382D1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren
WO2007067506A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
TW200610531A (en) Phthalazine derivatives as PARP inhibitors
MY169515A (en) Quinazolinedione derivatives as parp inhibitors
SE0301372D0 (sv) Novel compounds
SG154434A1 (en) Quinazolinone derivatives as parp inhibitors
SE0301700D0 (sv) Novel compounds
SE0101675D0 (sv) Novel composition
ATE479687T1 (de) Kinaseinhibitoren
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
NO20071915L (no) Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
AU2003228770A8 (en) Substituted pyrazolopyrimidines
EA200970156A1 (ru) Пиридизиноновые производные
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
TW200624426A (en) BACE inhibitors
TW200736227A (en) New compounds III
UA85505C2 (en) Kinase inhibitors
WO2007056625A3 (en) Thienopyridine b-raf kinase inhibitors
WO2007120333A3 (en) Tetracyclic kinase inhibitors
ATE507218T1 (de) Benzodiazepin-derivate als rock-kinasen hemmer
ATE274515T1 (de) Pyrazolopyridinderivate
ATE548364T1 (de) Aminopyrazolkinasehemmer
BRPI0615141A2 (pt) inibidores pentacìclicos de quinase
UA92180C2 (en) Benzimidazole thiophene compounds as plk inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties